The pharmacological management of anxiety disorders

Progress in Neurology and Psychiatry

Volumn 13, Issue 6, 2009, Pages 15-19

  Bleakley, Stephen ^a  

^a SOUTHERN HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; HYDROXYZINE; HYPNOTIC AGENT; LORAZEPAM; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; OXPRENOLOL; PAROXETINE; PHENELZINE; PLACEBO; PREGABALIN; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AKATHISIA; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; COGNITIVE THERAPY; DISEASE CLASSIFICATION; DIZZINESS; DRUG EFFICACY; GENERALIZED ANXIETY DISORDER; HUMAN; HYPOTENSION; INSOMNIA; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOTHERAPY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; TARDIVE DYSKINESIA; VOMITING; WEIGHT GAIN;

EID: 77949504560     PISSN: 13677543     EISSN: 1931227X     Source Type: Journal    
DOI: 10.1002/pnp.144     Document Type: Review

References (21)

1. Baldwin D, Anderson I, Nutt D, et al. Evidence-based guideline for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19:567-96.
2. National Institute for Health and Clinical Excellence. Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Clinical Guidelines 22. http://www.nice.org.uk (2004)
3. National Institute for Health and Clinical Excellence. Post Traumatic Stress Disorder (PTSD) Clinical Guideline 26. http://www.nice.org.uk (2005)
4. National Institute for Health and Clinical Excellence. Obsessive Compulsive Disorder. Clinical Guideline 31. http://www.nice.org.uk (2005)
5. Kapczinski FFK, Silva de Lima M, dos Santos Souza JJSS, et al. Antidepressants for generalized anxiety disorder. Cochrane Database of Systematic Reviews 2003, Issue 2.Art. No.: CD003592. DOI: 10.1002/14651858.CD003592.
6. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews 2006, Issue 1.Art. No.: CD002795. DOI: 10.1002/14651858.CD002795.pub2.
7. Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database of Systematic Reviews 2009, Issue 3.Art.No.: CD005170. DOI: 10.1002/14651858.CD005170.pub2
8. Bleakley S. Review of choice and use of antidepressants. Progress in Neurology and Psychiatry 2009;vol 13, issue 1:14-20
9. Soomro GM, Altman DG, Rajagopal S, Oakley Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD001765. DOI: 10.1002/14651858.CD001765.pub3
10. Nutt D, Malizia A. New insights into the role of the GABAA-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 2001;179:390-6.
11. Chief Medical Officer update Number 37. Patient safety. Benzodiazepine warning. www.dh.gov.uk (2004)
12. Darcis T, Ferreri M, Natens J, et al.A multicentre double-blind placebo controlled study investigating the anxiolytic efficacy of hydroxyzine in patients with generalized anxiety. Hum Psychopharmacol Clin 2005;10:181-7.
13. Parker C. Antipsychotics in the treatment of schizophrenia. Progress in Neurology and Psychiatry 2009;Vol 13, issue 2: 22-9.
14. Ipser JC, Carey P, Dhansay Y, et al. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database of Systematic Reviews 2006, Issue 4.Art. No.: CD005473. DOI: 10.1002/14651858.CD005473.pub2
15. Montgomery SA, Chatamra K, Pauer L, et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 2008;193:389-94.
16. Pande A, Crockatt J, Feltner D, et al. Pregabalin in generalized anxiety disorder: A placebo controlled trial. Am J Psychiatry 2003:160;533-40.
17. Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: A 6 week,multicenter, randomized, double blind, placebo controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67: 771-782
18. Chessick CA, Allen MH, Thase ME, et al. Azapirones for generalized anxiety disorder. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD006115. DOI: 10.1002/14651858.CD006115
19. Pitman R, Sanders K, Zusman R, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002;51:189-92.
20. Vaiva G, Ducrocq F, Jezequel K, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 2003;54:947-9.
21. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines 10th Edition. London: Informa Healthcare, 2009.